Symbolbild · KI-generiert
Pacira BioSciences, Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Pacira BioSciences is a pharmaceutical company specialising in non-opioid pain therapies. Its principal product Exparel is a liposomal bupivacaine for post-operative pain management, administered directly into the surgical site. The company also develops and markets additional products for pain management following surgical procedures.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Pacira BioSciences, Inc. | PCRX | NASDAQ | 1,04 Mrd. USD |
| Alpha Tau Medical Ltd. | DRTS | NASDAQ | 1,04 Mrd. USD |
| Cronos Group Inc. | CRON | TSX | 1,04 Mrd. USD |
| EyePoint, Inc. | EYPT | NASDAQ | 1,03 Mrd. USD |
| Alto Neuroscience, Inc. | ANRO | NYSE | 1,05 Mrd. USD |
| Lexicon Pharmaceuticals, Inc. | LXRX | NASDAQ | 1,03 Mrd. USD |
| Inventiva S.A. American Depository Shares | IVA | NASDAQ | 1,06 Mrd. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.